Search This Blog

Saturday, June 4, 2022

How Los Angeles became a hotbed for terrifying ‘follow home’ robberies

 For the past seven weeks, Donna Martin has kept vigil at the bedside of her son, Christopher Charles Martin.

Some days Christopher, 27, is able to move his limbs and his eyes, and Martin believes he is trying to comfort her when he hears her cry.

“Christopher has always been a protector,” said Martin. “He is very protective of me, and all of his family members.”

An entrepreneur and musician who performs under the name Donn Sway, Christopher founded a mentoring business to help boys who want to play college football assemble their college application materials. He also helped take care of his grandmother “in her final stages of dementia,” and always stood up for his younger brother Tyler, who suffers from schizophrenia, Martin recalled.

On April 15, Christopher’s protectiveness nearly cost him his life after he was shot in the head while trying to defend friends during a “follow-home” robbery — a trend that has terrorized Angelenos since last year.

Distinguished by their coordination and brutality, the attacks target people leaving upscale restaurants, hotels or posh clubs. The perpetrators often send “spotters” — individuals who look for well-dressed people with expensive jewelry, luxury cars or Rolex watches — to alert other gang members who entrap the victims.

Christopher Martin (with mom Donna) remains hospitalized after being shot in the head while trying to defend friends during a “follow-home” robbery.
Christopher Martin (with mom Donna) remains hospitalized after being shot in the head while trying to defend friends during a “follow-home” robbery.

“In many cases, the victims are not even having a chance to comply [and hand over their valuables],” Captain Jonathan Tippet, head of the LAPD’s Follow-Home Robbery Task Force, told The Post. “They are being tackled, punched, hit and pistol-whipped.”

One of the suspects shot Martin in the head after he tried to stop the robbers, according to Detective Daryn Dupree of the LAPD Robbery Homicide Special Section. “When we got the call that night, we thought Christopher was not going to make it,” said Dupree, noting that the young man’s survival has surpassed medical expectations.

A star athlete who played college football on full scholarship for UC Davis, Martin came from San Diego to LA April 15 to celebrate the birthday of a former UC Davis football player whom he had mentored.

“Coming from San Diego, Christopher may not have realized what the temperature is here,” said Dupree, referring to the crime wave.

Christopher was shot while defending friends outside Hyde Sunset nightclub in LA.
Christopher was shot while defending friends near Hyde Sunset nightclub in LA.

In 2021 the LAPD’s Robbery-Homicide Division noticed a surge of robberies involving multiple armed suspects coordinating to ambush victims, according to Tippet. He said that up to 18 gangs from South LA are involved.

“In my 34 years with the LAPD I have never seen this type of criminal behavior,” said Tippet, “with people in large groups … up to five carloads of individuals, and most of them appear to be armed, coordinating amongst themselves to target people.”

There have been 254 “follow-home” attacks since January 2021, Tippet said, with 165 occurring in 2021 — 111 of them in the final four months of last year and 89 this year to date.

Alarmed by the trend, Tippet established the Follow- Home Robbery Task Force in late November 2021.

Martin (far left) was a star athlete who played college football for UC Davis.
Martin (far left) was a star athlete who played college football for UC Davis.

Neighborhoods hit hardest are Downtown LA, Hollywood and the Wilshire District, including Melrose, a high-end shopping area. Victims have frequently been tourists, including those from Israel, Korea, the UK, Australia, Maryland, Florida, Philadelphia and Detroit, said Tippet.

The LAPD has seen “some reduction” in the number of follow-home robberies, especially those with “so many vehicles involved,” with 66 taking place in the first four months of this year. (Over the past four weeks there were 15.)

According to Tippet, the “follow-home” crime surge is attributable at least in part to reluctance on the part of the office of Los Angeles County District Attorney George Gascon to seek the stiffest possible sentences for suspected gang members. He has moved to deny “gang and gun enhancements” — provisions allowing prosecutors to seek longer prison sentences for gang-related crime or crime that causes grave bodily injury. Meanwhile, state policies have reduced bail requirement.

Chris (left) at his brother Michael's high school graduation.
Chris (left) at his brother Michael’s high school graduation.

“State policy is allowing violent criminals to post bail and not return to court for months, and during that time we know many are committing violent crimes,” Tippet said. “We’ve re-arrested some individuals who were out on bail after they’ve committed the same types of violent crimes.”

This “social justice” reluctance to utilize existing law to seek the stiffest possible sentences for violent crime suspects reflects a stinging irony when the majority of victims of the violent follow-home gang robbery trend have been minorities, Tippet maintained. According to the LAPD’s latest figures, 45 percent have been Black, 11 percent Hispanic, 5 percent Asian, 20 percent white, 17 percent other and 2 percent unknown.

“Hispanics, Blacks and Asians account for 62 percent of the victims of these violent armed gang robberies [since January 2021],” Tippet said. “[Gascon’s] saying he’s bringing social justice, but he isn’t bringing safety and protection to minorities.”

“In my 34 years with the LAPD I have never seen this type of criminal behavior,” said Captain Jonathan Tippet of LAPD's Follow Home Robbery Task Force.
“In my 34 years with the LAPD I have never seen this type of criminal behavior,” said Captain Jonathan Tippet of LAPD’s Follow Home Robbery Task Force.

Gascon’s office sent a statement maintaining that they are “deeply concerned” about follow-home robberies and asserting that asking if their office’s policies could be contributing to the violent crime wave is “dishonest and preposterous.”

“No one is saying: I would commit a crime because I might get a 10 or 20-year sentence, but I won’t do it if I will get a 40-year sentence,” wrote a spokeswoman for Gascon’s office. “People are worried about getting caught, and we are working with our law enforcement partners to make sure that happens.” 

Angelenos are critical of changes in the law and lax enforcement of existing law on the part of the Los Angeles County District Attorney.

Howard Rudich, 79, a recently retired Los Angeles jeweler, says he’s “relieved” to be out of business after 47 years due to the surge in break-ins and follow-home robberies. While jewelry salespeople often are robbed, the difference now is that “because the penalties are so relaxed, the gangs are emboldened to follow individual citizens … It’s an epidemic, and I link it to leftist policies. California leads the country in craziness.”

Some blame LA County DA George Gascon for not being strict enough on gang-related crime.
Some blame LA County DA George Gascon for not being strict enough on gang-related crime.
Carolyn Cole/Los Angeles Times/Shutterstock

Rudich added, “Most jewelers keep quiet about this because they don’t want the publicity; it keeps customers out of the store.

But [most jewelers] are scared to death.”

The suspects were “watching and stalking” Christopher Martin’s group, which included several former and current UC Davis college football players and an older male relative of one, who was driving a rented luxury SUV for the birthday celebration, according to Dupree.

The group had just left Hyde Sunset, a restaurant-nightclub on the Sunset Strip. Dupree believes the suspects were drawn to the group because of the chains worn by two of the young men.

Captain Tippet says the “follow-home” crime surge is attributable at least in part to reluctance on the part of the office of Gascon to seek the stiffest possible sentences for suspected gang members.
Captain Tippet says the “follow-home” crime surge is attributable at least in part to reluctance on the part of the office of Gascon to seek the stiffest possible sentences for suspected gang members.
CBS News

“Two of the guys had on a lot of jewelry,” said Dupree. “Gold. Christopher didn’t have any jewelry on. Christopher tried to stop them … But they were there to get the jewelry.”

After leaving the club at about 3 a.m., Christopher’s group walked to a lot on the Sunset Strip where they had parked because it was “less expensive” than parking at the club, said Dupree.

Christopher, who had come to the party in his own car, was standing outside the SUV and talking with the driver, when the suspects ran to the car, shouting “Give me the jewelry!” One of them pointed a gun at the driver — the older male relative of the man celebrating his birthday — “and Christopher yelled, ‘No! Stop!’” according to Dupree.

While it was “heroic” of Martin, who is a “special young man to try and intervene,” Dupree said, “We advise people to give up their jewelry or watches.”

Donna says her son Christopher (as a baby) is an “instinctually good person” who would have helped anyone.
Donna says her son Christopher (as a baby) is an “instinctually good person” who would have helped anyone.

He added, “I do respect the fact that Christopher tried to defend his friends—that shows the kind of person he is.”

Christopher’s mother Donna says that he is an “instinctually good person” who would have helped anyone.

She recalled that in 2019, when their family was out for dinner, Christopher “had a homeless man sit down with us” and said, ‘Tell me about your situation.’”

Christopher invited the man, who was about his age, to stay with him for a time, and gave him a suit to wear so he could interview to become a door-to-door salesman.

The LAPD created the Follow Home Robbery Task Force in November 2021 to deal with the new wave of crime.
The LAPD created the Follow Home Robbery Task Force in November 2021 to deal with the new wave of crime.
CBS News

Had they approached him and his friends without threat of violence, Martin believes Christopher would have helped his attackers.

“My son is a college educated, kind soul, and very sensitive,” said Martin. “They could have said, ‘You seem like you’re doing good in life,’ and … asked him for his help, and he would have given it to them.”

She said she is angry, and “forgiveness will be easier once [the perpetrators] are caught.”

She believes anyone who participated in the crime should go to prison.

Donna, with husband Michael, believes anyone who participated in the crime should go to prison.
Donna, with husband Michael, believes anyone who participated in the crime should go to prison.
John Chapple for NY Post

Martin, whose family has launched a GoFundMe to help cover Christopher’s medical expenses: speculated that the attackers “maybe didn’t have everything my son had, including a father, but that doesn’t excuse what they did, and what the District Attorney of Los Angeles [County] is doing for my son to be in this situation.

“I just want every person, no matter who they are, to serve time based on the crime.

“My son’s life is worth more than property and so is the life of any human being.”

https://nypost.com/2022/06/04/how-la-became-a-hotbed-for-terrifying-follow-home-robberies/

China's H&H working with FDA to up U.S. baby formula supplies

 Health and Happiness (H&H) International Holdings Ltd (1112.HK) is working closely with the U.S. Food and Drug Administration (FDA) to gain approval to send more infant formula supplies to the United States, a top executive said.

Top manufacturer Abbott Laboratories (ABT.N) in February recalled dozens of types of its Similac, Alimentum and EleCare formulas, creating one of the most urgent baby food shortages in recent history for U.S. families.

H&H, China’s fourth-biggest and the world’s tenth-largest infant formula supplier, has joined European rivals in stepping up shipments to address the shortage, according to Chief Strategy & Operations Officer Akash Bedi.

The maker of infant formula Biostime is “urgently working to provide assistance and is in the process of shipping infant formula from France and Australia to the U.S. to respond to the crisis,” Bedi said in an emailed statement.

“H&H is working closely with the FDA and other government bodies to gain approval and hope to be able to send products in the coming weeks,” he added.

The company has not seen any impact from the U.S. shortage in the Chinese market, Bedi added.

https://trendeepro.com/hh-working-with-fda-to-up-u-s-baby-formula-supplies/

Liquid Biopsy IDs Patients With Colon Cancer Who Can Skip Chemo

 A "liquid biopsy" that detects circulating tumor DNA (ctDNA) after surgery for stage 2 colon cancer helps identify patients who are most likely to benefit from adjuvant chemotherapy, and also identifies those who are unlikely to benefit allowing them to skip that treatment.

The results are from the phase 2 DYNAMIC trial.

"The strategy of using ctDNA results to inform treatment almost halved the number of patients who received chemotherapy postsurgery, from 28% down to 15%," commented first author Jeanne Tie, MD, from the Walter and Eliza Hall Institute of Medical Research at the Peter MacCallum Cancer Centre, University of Melbourne, Australia.

The overall proportion of patients who were alive and cancer-free at 3 years after ctDNA-guided treatment was 92% — the same as in patients randomized to standard management, she added.

The chance of being alive and cancer-free was 86.4% and 92.5%, respectively, in ctDNA-positive patients who received adjuvant chemotherapy and in ctDNA-negative patients who did not, she said. Conversely, the risk of recurrence is greater than 80% without treatment in ctDNA-positive patients, said Tie.

Tie reported the results here at the American Society of Clinical Oncology 2022 annual meeting, which were simultaneously published in the New England Journal of Medicine.

The study support a ctDNA-guided approach to treatment in this patient population, Tie said, noting that this approach addresses what has been a clinical dilemma: surgery can cure more than 80% of stage 2 patients, but the benefits of chemotherapy after surgery have been less clear — fewer than 1 in 20 patients will benefit, but the ability to predict which patients will benefit has been lacking.

The findings are practice-changing, commented Julie Gralow, MD, ASCO's chief medical officer and executive vice president.

"I see this study as an important kind of new concept in cancers, where for the most part we have really very good survival and outcomes...and now we're starting to look at ways we can deescalate therapy in a subgroup who we know are going to do well while continuing the more intensive therapy, or even escalating therapy, in the group who we know are not going to do well with our conventional therapies," Gralow said at a press briefing where the study was highlighted.

"I do believe the results are going to help us guide our selection of who benefits from chemo and who can avoid it — and all the toxicities of it — in stage 2 colon cancer," she added.

They may also identify patients who may need more than standard treatment. This is a group in which "we might need to think outside the box and do even more besides just thinking about adjuvant chemo," she told Medscape Medical News in a preconference interview. "Maybe this is a group we should be thinking about adjuvant immunotherapy, for example, or adjuvant EGFR-targeted therapy, or other things that we have shown [to have benefit] in the metastatic setting."

Study Details

For the DYNAMIC trial, Tie and colleagues enrolled 455 patients with resected stage 2 colon cancer at multiple centers between August 2015 and August 2019. Of those, 302 were randomized to receive ctDNA-guided chemotherapy and 153 received standard management based on conventional criteria, including tumor stage of disease, number of lymph nodes assessed, whether the tumor had perforated the bowel wall, and other factors.

The Safe-SeqS tumor-informed personalized ctDNA assay was used to detect ctDNA in the experimental group. Patients with a ctDNA-positive result at 4 or 7 weeks after surgery received oxaliplatin-based or fluoropyrimidine chemotherapy; those who were ctDNA-negative were observed during follow-up.

Fewer patients overall in the ctDNA-guided group, compared with the standard management group, received adjuvant chemotherapy (15.3% vs 27.9%; odds ratio, 2.14).

Two-year recurrence-free survival (RFS) in the ctDNA-guided treatment group was noninferior to that in the standard management group (93.5% vs 92.4%). Three-year RFS was 86.4% in ctDNA-positive patients who received chemotherapy, 92.5% in ctDNA-negative patients without chemotherapy, and 96.7% in a clinical low-risk subgroup.

ASCO expert Cathy Eng, MD, applauded the findings, stating in a press release that "thanks to the results of this study, we may now be able to use it to better identify which patient with stage 2 colon cancer would benefit from post-surgery treatment with chemotherapy and which ones can be spared the additional treatment, without compromising relapse-free survival."

Eng is the David H. Johnson Chair in Surgical and Medical Oncology, co-leader of the Gastrointestinal Cancer Research Program, co-director of GI oncology, and professor of medicine in hematology and oncology at Vanderbilt University, Nashville, Tennessee.

Next Steps

The authors note that a randomized trial is being considered in which ctDNA-positive and -negative patients would be randomized to treatment versus no treatment. This could provide more definitive evidence of treatment impact, or lack of impact, in each of the patient subsets, according to the press release.

The DYNAMIC trial was funded by the Australian National Health and Medical Research Council, US National Institutes of Health, the Marcus Foundation, the Virginia and D.K. Ludwig Fund for Cancer Research, Lustgarten Foundation, the Conrad R. Hilton Foundation, the Sol Goldman Charitable Trust, John Templeton Foundation, and Eastern Health Research Foundation. Tie has reported receiving honoraria from Inivata and Servier, and serving as a consultant or advisor for AstraZeneca/MedImmune, Bristol-Myers Squibb, Haystack Oncology, Inivata, MSD Oncology, and Pierre Fabre.  

ASCO 2022. Abstract LBA100. Presented June 4, 2022.

N Engl J Med. Published online June 4, 2022. Full text

https://www.medscape.com/viewarticle/975058

Biotech Layoff Tracker

 The pace of biotech layoffs is coming so fast that even we at Fierce Biotech could not write our feature on the issue fast enough to encapsulate them all. As we hit publish on our story, more companies announced they were letting staff go.

Every single day, we’re seeing new companies announce that, regrettably, they will have to cut back on head count. C-suites have not been immune, either, with a few companies relieving key leaders of their duties as they restructure to face a tumultuous market and make or break regulatory or research moments.

So today, we’re launching our Fierce Biotech Layoff Tracker. We’re starting from Jan. 1 of this year, and we’ll see where it goes.

If you have information about a layoff happening at a biotech, please let Senior Editor Annalee Armstrong know and we’ll check it out.

June—2 companies so far

NEW—June 3, 2022: Athersys: The stem cell biotech is going straight for the big ax, cutting 70% of staff and most of its C-suite after the stroke therapy MultiStem failed in a phase 2/3 trial in May.

June 2, 2022: Atreca: The oncology biotech plans to cull a quarter of its workforce, a move that includes both current employees and open positions. The cuts are part of a corporate reorganization announced June 1 that aims to fund the company through 2023.

 

May—5 companies total

May 14, 2022: Genocea: Less than a month after dwindling funds forced Genocea to ax 65% of its staff and seek out a sale, the company is officially closing up shop. The move means all remaining nonessential staff will be shown the door and the company will de-list from Nasdaq. 

May 18, 2022: Applied Molecular Transport: The biopharmaceutical company is cutting 40% of staff, bringing its full-time workforce to 81 employees. AMT co-founder and Chief Scientific Officer Randall Mrsny, Ph.D., is also departing after more than a decade with the company.

May 17, 2022: Scholar Rock: The protein growth factor biotech is in a hard place, with plans to lay off 25% of staff, trim the pipeline and send CMO Yung Chyung, M.D., out the door. 

May 16, 2022: Agios Pharmaceuticals: After offloading its cancer business and snagging an FDA approval for Pyrukynd, Agios is looking to shake up its R&D operations to focus more on later-stage assets. That means 50 employees will lose their jobs, while 50 other R&D personnel will remain to drive the new focus

May 3, 2022: Spero Therapeutics: A tough call from the FDA on its urinary tract infection drug tebipenem HBr led Spero to announce it will lay off 75% of its staff. The cuts will reduce the biotech's headcount from a full-strength total of 146 to just 35 full-time employees.

 

April—17 companies total
 

Genocea Biosciences: A few weeks ago, Genocea Biosciences was touting phase 1/2 data. Now, 65% of the workforce is headed out the door and the biotech is looking to sell itself.

Solid Biosciences: Another biotech re-prioritization will cost staff at Solid Biosciences, as the company reduces its workforce by 30% to refocus efforts on two key Duchenne muscular dystrophy programs.

Nektar Therapeutics: After a $3.6 billion immuno-oncology partnership with Bristol Myers Squibb crumbled, Nektar has had to make some difficult choices. The company has gutted its workforce by 70% and two key executives will depart. 

Black Diamond Therapeutics: After initially de-prioritizing a precision oncology drug in January, Black Diamond is calling it quits on the program. Along with a re-prioritization, the biotech will lay off 30% of its staff. 

Imara: Only six employees will remain at Boston-based Imara after 83% of its staff are cut. The company is reeling from the discontinuation of development for lead drug tovinontrine, or IMR-687, in sickle cell disease, beta-thalassemia and heart failure with preserved ejection fraction. 

Finch Therapeutics: After a collection of setbacks, Finch is letting go 20% of its workforce. The layoffs, which are expected to be complete by the end of the second quarter, will impact about 37 full time employees. 

Sio Gene Therapies: The majority of staff at Sio Gene Therapies were let go during an all hands meeting, the biotech said April 27. 

Magenta Therapeutics: Magenta is saying farewell to 14% of its staff as the company focuses on its targeted conditioning stem cell program as well as its mobilization and collection asset for sickle cell. 

ProQR: Ophthalmology-focused ProQR is cutting 30% of its staff, including Chief Scientific Officer Naveed Shams, M.D., Ph.D., as the company re-strategizes following a phase 2/3 setback two months ago. 

Stryker: 88 workers have lost their jobs at a facility in Florida as part of rolling layoffs at medtech giant Stryker. 

PerkinElmer: As a COVID-19 testing contract winds down with the state of California, PerkinElmer is letting 75 people go effective June 4. The lab services giant is closing down operations at the California Department of Public Health’s laboratory in Valencia, a neighborhood of Los Angeles County.

Kaleido: After a dismal last eight months, microbiome-focused Kaleido Therapeutics is closing up shop and axing the rest of its workforce, including the CEO, CFO and CSO. The update comes a few months after the company trimmed its staff to stave off what increasingly seemed like an inevitable end after numerous ruptures to its pipeline. The company had accumulated a deficit that exceeded $360 million, acccording to its latest annual report.

Akebia: After a partial clinical hold and an FDA rejection, Akebia is cutting 42% of its workforce across “all areas of the company."

Sanofi: The French pharma disclosed in a New York Worker Adjustment and Retraining Notification (WARN) notice dated March 31 (PDF) that 25 workers would be "dislocated" due to a plant closing in the state. The layoffs stem from the $1.9 billion acquisition of Kadmon, which Sanofi closed in November 2021. The filing said that the employees would be cut due to an integration of resources and the business would be permanently closing. The layoffs will begin on July 1 and wrap up by April 1, 2023. 

Catalyst Biosciences: The company is at a corporate crossroads, emblematic in the decision to switch up its pipeline and call for strategic alternatives. As a part of the soul-searching, 19 employees or 70% of remaining staff have lost their jobs, according to an earnings report released March 31.

Bluebird bio: A few weeks after its spinout announced layoffs, the same happened at bluebird. Facing several regulatory setbacks, the company is cutting 30% of its workforce. 

Novartis: A major restructuring is underway at Novartis, with several high profile executives caught up in the changes. The cuts will trigger some broader job losses as well, but the company has so far been mum on the details. 

 

March—17 companies total
 

Taysha Gene Therapies: Pink slips were handed out to about 35% of workers at Taysha in March as the biotech slimmed down its R&D focus. 

Zealand Pharma: After a new drug launch went sideways, Zealand had to reduce its workforce by a whopping 90%.

Bone Therapeutics: About a quarter of Bone's workforce was let go in early March as the biotech scrambled to save cash

BridgeBio Pharma: After a disappointing phase 3 result stunned the company at the end of last year, BridgeBio cut an undisclosed number of employees. 

Silverback Therapeutics: A restructuring led to a 27% workforce reduction at Silverback, the biotech said at the end of March. Two clinical oncology programs were also shelved. 

Merck & Co.: The company's Acceleron buyout ranked among the biggest deals of 2021, but Merck nevertheless moved to cut about 143 employees from the unit at the end of March. 

2seventy bio: The newly- spun out biotech confirmed in late March that about 6% of its workforce would be let go in an effort to reduce overhead costs. 

Orion: Another pipeline refocus claimed about 37 employees in late March as the company pivoted to cancer and pain. 

Zosano: About 31% of staff was cut from Zosano's bench, according to a March 17 earnings release, as the biotech explored strategic options. 

Athenex: In an effort to lower operating costs by 50%, Athenex cut its workforce, although details were slim in the March 16 earnings release. 

Ovid Therapeutics: After a rough year, Ovid announced a new focus on its epilepsy- and seizure-related programs in March, saying 20% of staff would be cut in the process. 

Passage Bio: The gene therapy biotech trimmed its workforce by 13% and doubled down on a partnership with James Wilson, M.D., Ph.D., and his University of Pennsylvania lab in March. 

Orphazyme: Struggling Danish meme stock biotech Orphazyme announced a second round of layoffs in March amid a court-mediated restructuring.

Adaptive Biotechnologies: About 100 workers lost their jobs at Adaptive in March as the biotech trimmed down to focus on minimal residual disease and immune medicine.

Gilead Sciences: Another Big Pharma caught up in the trend, Gilead laid off 114 workers based out of the former Immunomedics headquarters in New Jersey. 

Biogen: After a tumultuous nine months marked by a controversial Alzheimer's disease approval and difficult launch for Aduhelm—not to mention several clinical flops—Biogen's restructuring snared an undisclosed number of staffers in March. 

Epizyme: Two clinical studies and 12% of staff went out the door at Epizyme when the company reported earnings March 1. 

 

February—5 companies total
 

Gemini Therapeutics: President and CEO Jason Meyenburg departed Gemini along with 24 employees in late February. 

Yumanity: Sixty percent of Yumanity's workforce is expected to leave by April as the neurodegenerative-focused biotech seeks a buyer, the company said in February. 

Metacrine: After a NASH failure last year, Metacrine halved its staff and adjusted to focus on inflammatory bowel disease in February.

Biosplice: Once worth $12 billion, Biosplice laid off 41 workers in early February and culled a male pattern baldness drug.

Unity Biotechnology: The anti-aging biotech once again laid off workers in early February, with half of the staff getting the cut. The company also reprioritized to focus on ophthalmology.

 

January—8 companies total
 

Gamida Cell: This late January wave of layoffs was cushioned by some good news: Gamida Cell was initiating a rolling FDA submission for the blood cancer treatment omidubicel. But the biotech would need help from strategic partners and a 10% reduction in head count to get the filing across the finish line.


Kaleido Biosciences
: Flagship Pioneering-incubated Kaleido shrank its workforce, halted a planned phase 2 trial and terminated an agreement with the COPD Foundation in January. 

Zymeworks: New CEO Kenneth Galbraith quickly wielded the ax to reduce headcount by 25% and halve the cancer biotech's C-suite in January, just days after taking over the executive job. 

Acutus Medical: A number of employees lost their jobs Jan. 19 when Acutus Medical moved to slash tens of millions of dollars from its annual operating expenses. The company did not disclose the full toll, but said they would be required to file a public disclosure under the Worker Adjustment and Retraining Notification (WARN) Act, which requires 60-day notice before employers lay off at least 50 workers.

Leo Pharma: Leo Pharma announced some major restructuring on Jan. 19 that hit about 68 employees right away. But the reorganization could ultimately affect 1,000 positions over the next two years. The company is shutting down its regenerative medicine innovation hub and science and tech centers in Asia and Boston. 

Daiichi Sankyo: Cuts at the Japanese pharmaceutical company announced Jan. 12 impacted about 60 employees. The company shut down its Plexxikon R&D operation in South San Francisco, 10 years after buying the biotech for $805 million upfront.

BeyondSpring: The biotech axed 35% of its U.S. staff on Jan. 12 after the FDA rejected its chemotherapy-induced neutropenia drug called plinabulin.  

Spectrum Therapeutics: Spectrum announced a 30% staff cut Jan. 5 in an effort to save cash and focus on mid- and late-stage cancer meds. The move followed an FDA rejection in August 2021. 

https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2022